INmune Bio jumps 22.13% premarket on MINDFuL trial efficacy in inflamed Alzheimer’s patients and FDA alignment for Phase 2b/3.

INmune Bio Inc. surged 22.13% in premarket trading following the announcement that its Phase 2 MINDFuL trial of XPro1595 (pegipanermin) was highlighted in a plenary presentation at the AD/PD 2026 conference. The trial demonstrated consistent efficacy signals in an inflamed patient subgroup enriched for inflammatory biomarkers, aligning with the drug’s mechanism of targeting soluble TNF. The company also secured FDA alignment to advance an integrated Phase 2b/3 registrational program for early Alzheimer’s patients. The plenary, led by respected neuroimmunologist Dr. Malú Gámez Tansey, emphasized the trial’s role as a blueprint for precision drug development by linking biomarker enrichment to therapeutic response. These developments underscore INmune Bio’s progress in validating its Alzheimer’s treatment strategy and regulatory pathway, directly driving investor optimism.